EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of QuantiFERON-TB Gold Plus results using ELISA and automated CLIA detection: a 39,000-sample real-world study

Federica Sorella iD, Vincenzo Ferraro iD, Paolo Caiazza iD, Miriam Ciccarelli, Giuliana Germinario iD, Alessia Cantiani iD, Giulia Lombardi, Francesco Bisognin iD, Paola Dal Monte iD

Microbiology Spectrum · 03.11.2026 · 14 (11)

DOI: 10.1128/spectrum.02295-26 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Microbiology Spectrum, erschienen am 03.11.2026. Verfasst von Federica Sorella und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science and Surgery, Alma Mater Studiorum - University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Tuberculosis, Mycobacterium tuberculosis, Interferon-gamma Release Tests, Luminescent Measurements. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

QuantiFERON-TB Gold Plus (QFT-Plus) is a widely used interferon-γ release assay (IGRA) for the diagnosis of Mycobacterium tuberculosis infection. Recent advances introduced fully automated chemiluminescence immunoassay (CLIA) platforms as alternatives to conventional enzyme-linked immunosorbent assay (ELISA), potentially improving analytical performance and laboratory workflow. This study compared ELISA- and CLIA-based QFT-Plus assays using both lyophilized and liquid conjugate formulations in routine clinical practice. This retrospective study included 39,604 QFT-Plus assays performed during three distinct 1-year periods: 2019 (ELISA), 2023 (CLIA with lyophilized conjugate), and 2024 (CLIA with liquid conjugate). Test results were classified as positive, negative, or indeterminate. Indeterminate results were further categorized as due to low mitogen response (LMR) or high Nil value (HNV). Indeterminate results significantly decreased from 6.5% (777/11,885) with ELISA to 3.1% (394/12,690) with CLIA test using lyophilized conjugate and 3.1% (470/15,029) of CLIA tests using the liquid conjugate ( P < 0.0001). Positive results accounted for 10.6 (1,254/11,885), 10.3 (1,312/12,690), and 9.0% (1,355/15,029) of tests, respectively. Among indeterminate results, LMR accounted for 97.3% (756/777) with ELISA, whereas HNV accounted for 27.4 (108/394) and 16.8% (79/470) with the lyophilized- and liquid-conjugate CLIA methods, respectively. Agreement between TB1 and TB2 responses was consistently high across all methods (98.5–98.8%; κ = 0.92). CLIA-based QFT-Plus assays were significantly associated with a lower proportion of indeterminate results while maintaining an excellent TB1/TB2 concordance compared with ELISA. These findings support fully automated CLIA platforms as a robust and efficient alternative to conventional ELISA for high-throughput tuberculosis screening and routine clinical diagnostics. IMPORTANCE This study provides a large real-world evaluation of QuantiFERON-TB Gold Plus testing across different analytical platforms, including more than 39,000 tests performed in routine clinical practice. The transition from conventional enzyme-linked immunosorbent assay (ELISA) to automated chemiluminescence immunoassay (CLIA) was associated with an approximately 50% decrease in indeterminate results from 6.5 to 3.1%, with similarly low rates observed using both lyophilized and liquid conjugate formulations. Beyond documenting this substantial reduction, our study reveals a marked difference in the causes of indeterminate results: low mitogen response predominated with ELISA, whereas high Nil values accounted for a larger proportion of indeterminate results with CLIA. These findings, interpreted together with our previous paired-sample comparison, indicate that differences in quantitative IFN-γ measurement across platforms may affect how samples are classified against fixed decision thresholds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisMycobacterium tuberculosisInterferon-gamma Release TestsLuminescent MeasurementsHumansEnzyme-Linked Immunosorbent AssayRetrospective StudiesSensitivity and SpecificityInterferon-gamma

Stichwörter der Autor:innen

ELISAQuantiFERON-TB Pluschemiluminescence immunoassay (CLIA)indeterminate resultsinterferon-gamma release assaytuberculosis

Substanzen

Interferon-gamma

Autor:innen und Institutionen

  • Department of Medical Science and Surgery, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
  • Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Federica Sorella, Vincenzo Ferraro, Paolo Caiazza, Giuliana Germinario, Alessia Cantiani, Francesco Bisognin, Paola Dal Monte

Zitieren

APA

Sorella, F., Ferraro, V., Caiazza, P., Ciccarelli, M., Germinario, G., Cantiani, A., Lombardi, G., Bisognin, F., & Dal Monte, P. (2026). Comparison of QuantiFERON-TB Gold Plus results using ELISA and automated CLIA detection: a 39,000-sample real-world study. Microbiology Spectrum, 14(11). https://doi.org/10.1128/spectrum.02295-26

Vancouver

Sorella F, Ferraro V, Caiazza P, Ciccarelli M, Germinario G, Cantiani A, et al. Comparison of QuantiFERON-TB Gold Plus results using ELISA and automated CLIA detection: a 39,000-sample real-world study. Microbiology Spectrum. 2026;14(11). doi:10.1128/spectrum.02295-26

BibTeX
@article{Sorella2026,
  author = {Sorella, Federica and Ferraro, Vincenzo and Caiazza, Paolo and Ciccarelli, Miriam and Germinario, Giuliana and Cantiani, Alessia and Lombardi, Giulia and Bisognin, Francesco and Dal Monte, Paola},
  title = {Comparison of QuantiFERON-TB Gold Plus results using ELISA and automated CLIA detection: a 39,000-sample real-world study},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1128/spectrum.02295-26}
}
Kostenlos starten →